Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Ginwa Enterprise Group's 3-Year RORE % for the quarter that ended in Mar. 2026 was 106.60%.
The industry rank for Ginwa Enterprise Group's 3-Year RORE % or its related term are showing as below:
SHSE:600080's 3-Year RORE % is ranked better than 91.8% of 939
companies
in the Drug Manufacturers industry
Industry Median: 3.09
vs SHSE:600080: 106.60
Ginwa Enterprise Group (SHSE:600080) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Ginwa Enterprise Group 3-Year RORE % Related Terms
Ginwa Enterprise Group 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:600080 vs ZTS, UTHR: 3-Year RORE % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ginwa Enterprise Group's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ginwa Enterprise Group 3-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ginwa Enterprise Group's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Ginwa Enterprise Group's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Ginwa Enterprise Group (SHSE:600080) has a 3-Year RORE % of 106.60 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Ginwa Enterprise Group and its competitors. According to the industry distribution chart, Ginwa Enterprise Group ranks #77 out of 939 companies in the Drug Manufacturers industry, placing it in the top 8.2%.
Is Ginwa Enterprise Group's 3-Year RORE % too high?
Ginwa Enterprise Group's current 3-Year RORE % is 106.60. The Drug Manufacturers industry median 3-Year RORE % is 3.09. Ginwa Enterprise Group's value of 106.60 is 3349.8% above this industry median. Based on the distribution chart, Ginwa Enterprise Group ranks #77 out of 939 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Ginwa Enterprise Group has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ginwa Enterprise Group's 3-Year RORE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ginwa Enterprise Group ranks #77 out of 939 companies for 3-Year RORE %. This places Ginwa Enterprise Group in the top 8% of its industry — outperforming the majority of peers. The industry median 3-Year RORE % is 3.09. Ginwa Enterprise Group's value of 106.60 is 3349.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 3.09, based on 939 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ginwa Enterprise Group's current 3-Year RORE % of 106.60 is 3349.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Ginwa Enterprise Group and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 3.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ginwa Enterprise Group's current 3-Year RORE % is 106.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ginwa Enterprise Group stock overvalued right now?
Based on GuruFocus' analysis, Ginwa Enterprise Group (SHSE:600080) is currently considered Possible Value Trap. The stock's GF Value™ is ¥7.53, compared to a current price of ¥4.72 — trading 37.3% below its estimated fair value. The current 3-Year RORE % is 106.60 and 3349.8% above the Drug Manufacturers industry median of 3.09. Ginwa Enterprise Group's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Ginwa Enterprise Group (SHSE:600080), the current 3-Year RORE % is 106.60 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ginwa Enterprise Group (SHSE:600080) Overvalued in 2026?
Based on GuruFocus' analysis, Ginwa Enterprise Group stock appears to be undervalued.
The current stock price of ¥4.72 is trading 37.3% below its estimated GF Value™ of ¥7.53.
GuruFocus considers Ginwa Enterprise Group to be Possible Value Trap.
Key valuation signals for SHSE:600080:
3-Year RORE %: 106.60
GF Value™: ¥7.53 vs. price of ¥4.72 (37.3% below fair value)
Industry Position: 3349.8% above the Drug Manufacturers median (#77 of 939)
No single metric tells the full story. See the SHSE:600080 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ginwa Enterprise Group Inc operates in the pharmaceutical industry. The main business is the research and development, production, and sales of drugs, and the product line covers chemical drugs, Chinese patent medicines, raw materials, and health products. The dosage forms include tablets, capsules, granules, powders, mixtures, oral solutions, syrups, external solutions, and more than 100 varieties and specifications.
48GF Score
Get the complete analysis for SHSE:600080
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600080 has been successfully added to your 
